ProQR Therapeutics N.V.

PRQR

NL0010872495

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
2.01 ^USD	-0.50%		+5.79%	+1.52%

Mar. 14	Chardan Raises ProQR Therapeutics' PT to $2.50 From $2, Says ADAR-Based Therapeutics to Enter Clinical Development, Keeps Buy Rating	MT
Mar. 13	ProQR Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

ProQR Therapeutics N.V.(NasdaqGM:PRQR) added to NASDAQ Biotechnology Index

December 20, 2021 at 12:00 am EST

ProQR Therapeutics N.V. has been added to NASDAQ Biotechnology Index.

Latest news about ProQR Therapeutics N.V.

Chardan Raises ProQR Therapeutics' PT to $2.50 From $2, Says ADAR-Based Therapeutics to Enter Clinical Development, Keeps Buy Rating	Mar. 14	MT
ProQR Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
ProQR Therapeutics N.V. and Rett Syndrome Research Trust Join Forces with Axiomer RNA Editing Collaboration	Jan. 05	CI
ProQR Therapeutics Completes Divestment of Two Ophthalmic Assets to Laboratoires Thea	Dec. 08	MT
Laboratoires Théa S.A.S. acquired Sepofarsen and Ultevursen Ophthalmic Assets from ProQR Therapeutics N.V. for approximately ?170 million.	Dec. 06	CI
Raymond James Adjusts ProQR Therapeutics' Price Target to $4 From $5, Keeps Outperform Rating	Nov. 08	MT
Chardan Upgrades ProQR Therapeutics to Buy From Neutral, Price Target is $2	Nov. 08	MT
ProQR Therapeutics N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
ProQR Therapeutics Granted US Patent Expanding Protection of RNA Editing Technology	Nov. 06	MT
ProQR Therapeutics Says Sale of Ophthalmic Assets to Laboratoires Thea Terminated	23-09-27	MT
Laboratoires Théa S.A.S. cancelled the acquisition of Sepofarsen and Ultevursen Ophthalmic Assets from ProQR Therapeutics N.V..	23-09-26	CI
Citigroup Adjusts ProQR Therapeutics' Price Target to $1.80 From $2.10, Keeps Neutral Rating	23-09-18	MT
ProQR Therapeutics N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Laboratoires Théa S.A.S. agreed to acquire Sepofarsen and Ultevursen Ophthalmic Assets from ProQR Therapeutics N.V. for approximately ?135 million.	23-07-31	CI
Chardan Assigns New Price Target of $2 to ProQR Therapeutics, Keeps Neutral Rating	23-05-24	MT
ProQR Therapeutics N.V. Approves the Appointment of Theresa Heggie and Begoña Carreño as Supervisory Board Member	23-05-17	CI
Cantor Fitzgerald Adjusts Price Target on ProQR Therapeutics to $4.50 From $5, Maintains Overweight Rating	23-05-17	MT
ProQR Therapeutics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-16	CI
HC Wainwright Raises Price Target on ProQR Therapeutics to $5 From $1.50, Maintains Buy Rating	23-03-30	MT
ProQR Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29	CI
Transcript : ProQR Therapeutics N.V. - Special Call	23-03-29
Proqr Therapeutics N.V. Announces Initial Pipeline Targets and Highlights Axiomer RNA Editing Platform Technology At R&D Event	23-03-29	CI
ProQR Therapeutics Wins Hearing on Key Patent for Axiomer	23-03-14	MT
ProQR Therapeutics N.V. Announces Successful Defense of Key Axiomer(R) Patent Protecting Adar-Mediated RNA Editing	23-03-14	CI
Raymond James Adjusts ProQR Therapeutics Price Target to $5 From $2, Maintains Outperform Rating	22-12-23	MT

ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leberâs congenital amaurosis (LCA).

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - American Society of Gene & Cell Therapy Meeting - Poter No. 705

More about the company

Income Statement Evolution

More financial data

Ratings for ProQR Therapeutics N.V.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.01 USD

Average target price

4.1 USD

Spread / Average Target

+103.98%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PROQR THERAPEUTICS N.V.	+1.52%	164M
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	104B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.42B
ARGENX SE	+1.46%	22.2B
BIONTECH SE	-16.53%	21.23B
GENMAB A/S	-8.89%	18.33B
WUXI APPTEC CO., LTD.	-42.33%	16.35B
BEIGENE, LTD.	-20.09%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	13.98B
SAREPTA THERAPEUTICS, INC.	+28.85%	11.66B

Bio Therapeutic Drugs